Buscador de publicacions

Publicacions

  • Pascual-Pastó G, Gene-Olaciregui N, Vilà-Ubach M, Paco-Mercader S, Monterrubio C, Rodriguez E, Winter U, Batalla-Vilacís M, Català-Mora J, Salvador-Hernandez H, Parareda A, Schaiquevich P, Suñol M, Mora J, Lavarino C, de Torres C, Chantada G and Carcaboso AM.

    Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination

    CANCER LETTERS . 380(1): 10-19. Nº de cites: 23

    [doi:10.1016/j.canlet.2016.06.012]

  • Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen ML, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW and Taylor MD.

    Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis

    JOURNAL OF CLINICAL ONCOLOGY . 34(21): 2468-2477. Nº de cites: 141

    [doi:10.1200/JCO.2015.65.7825]

  • Hernandez-Muñoz I, Figuerola-Bou E, Sánchez-Molina S, Rodriguez E, Fernández-Mariño AI, Pardo-Pastor C, Bahamonde MI, Fernández-Fernández JM, García-Domínguez DJ, Hontecillas-Prieto L, Lavarino C, Carcaboso AM, de Torres C, Tirado OM, de Alava E and Mora J.

    RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-?B pathway, independently of the fusion oncoprotein

    Oncotarget . 7(29): 46283-46300. Nº de cites: 12

    [doi:10.18632/oncotarget.10092]

  • Bautista F, Gallego S, Cañete A, Mora J, Diaz de Heredia C, Cruz-Martínez O, Fernández JM, Rives-Solà S, Madero L, Castel V, Cela ME, Ramírez G, Sábado C, Acha T, Astigarraga I, Sastre A, Muñoz A, Guibelalde M and Moreno L.

    Landscape of early clinical trials for childhood and adolescence cancer in Spain

    CLINICAL & TRANSLATIONAL ONCOLOGY . 18(7): 708-713. Nº de cites: 4

    [doi:10.1007/s12094-015-1421-9]

  • Brandt A, Löhers K, Beier M, Leube B, de Torres C, Mora J, Arora P, Jat PS and Royer-Pokora B.

    Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15

    PLoS One . 11(5): . Nº de cites: 5

    [doi:10.1371/journal.pone.0155561]

  • Mora J.

    Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma

    EXPERT REVIEW OF CLINICAL PHARMACOLOGY . 9(5): 647-653. Nº de cites: 39

    [doi:10.1586/17512433.2016.1160775]

  • Millan NC, Poveda MJ, Cruz-Martínez O and Mora J.

    Safety of bevacizumab in patients younger than 4 years of age

    CLINICAL & TRANSLATIONAL ONCOLOGY . 18(5): 464-468. Nº de cites: 11

    [doi:10.1007/s12094-015-1389-5]

  • Lasorsa VA, Formicola D, Pignataro P, Cimmino F, Calabrese FM, Mora J, Esposito MR, Pantile M, Zanon C, De Mariano M, Longo L, Hogarty MD, de Torres C, Tonini GP, Iolascon A and Capasso M.

    Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression

    Oncotarget . 7(16): 21840-21852. Nº de cites: 64

    [doi:10.18632/oncotarget.8187]

  • Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AA, Giannini C, Li KK, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DC, Seow WT, Chang KT, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fèvre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobágyi T, Klekner A, László B, Pócza T, Hauser P, Schüller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen MC, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, López-Aguilar E, Lyden D, Garzia L, Shih DJ, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DT, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V and Taylor MD.

    Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

    LANCET ONCOLOGY . 17(4): 484-495. Nº de cites: 241

    [doi:10.1016/S1470-2045(15)00581-1]

  • Krauel L, Fenollosa F, Riaza L, Pérez M, Tarrado X, Morales-La Madrid A, Gomà J and Mora J.

    Use of 3D Prototypes for Complex Surgical Oncologic Cases

    WORLD JOURNAL OF SURGERY . 40(4): 889-894. Nº de cites: 39

    [doi:10.1007/s00268-015-3295-y]